Shares of Penumbra Inc (NYSE:PEN) have earned an average broker rating score of 1.40 (Strong Buy) from the five analysts that provide coverage for the stock, Zacks Investment Research reports. One analyst has rated the stock with a hold rating and four have issued a strong buy rating on the company. Penumbra’s rating score has declined by 40% from three months ago as a result of a number of analysts’ ratings changes.

Brokerages have set a 12-month consensus target price of $115.00 for the company and are forecasting that the company will post ($0.01) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Penumbra an industry rank of 111 out of 265 based on the ratings given to related companies.

Several brokerages have commented on PEN. Canaccord Genuity upped their price objective on Penumbra from $100.00 to $113.00 and gave the company a “buy” rating in a research report on Wednesday, November 8th. BMO Capital Markets upped their target price on Penumbra from $96.00 to $117.00 and gave the stock an “outperform” rating in a report on Wednesday, November 8th. Zacks Investment Research upgraded Penumbra from a “sell” rating to a “hold” rating in a report on Wednesday, October 11th. Finally, BidaskClub cut Penumbra from a “buy” rating to a “hold” rating in a report on Friday, August 18th.

In related news, EVP Robert D. Evans sold 4,983 shares of the company’s stock in a transaction on Thursday, September 21st. The stock was sold at an average price of $90.00, for a total transaction of $448,470.00. Following the completion of the sale, the executive vice president now directly owns 11,704 shares in the company, valued at approximately $1,053,360. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Thomas Wilder sold 345 shares of the company’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $90.20, for a total value of $31,119.00. The disclosure for this sale can be found here. Insiders sold a total of 301,079 shares of company stock valued at $31,150,834 over the last quarter. Company insiders own 13.50% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Penumbra by 10.9% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,159 shares of the company’s stock worth $102,000 after purchasing an additional 114 shares during the last quarter. Verition Fund Management LLC purchased a new stake in shares of Penumbra during the 2nd quarter worth $213,000. Teacher Retirement System of Texas purchased a new stake in shares of Penumbra during the 3rd quarter worth $214,000. Ameritas Investment Partners Inc. lifted its stake in shares of Penumbra by 10.8% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,573 shares of the company’s stock worth $226,000 after purchasing an additional 250 shares during the last quarter. Finally, Prudential Financial Inc. acquired a new position in Penumbra during the 2nd quarter valued at about $252,000. Hedge funds and other institutional investors own 71.71% of the company’s stock.

Shares of Penumbra (NYSE:PEN) traded up $2.95 during trading on Friday, reaching $98.70. The company’s stock had a trading volume of 256,517 shares, compared to its average volume of 191,757. Penumbra has a 12 month low of $62.43 and a 12 month high of $116.35.

Penumbra (NYSE:PEN) last announced its quarterly earnings data on Tuesday, November 7th. The company reported $0.01 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.06) by $0.07. The company had revenue of $83.90 million for the quarter, compared to the consensus estimate of $79.17 million. Penumbra had a negative return on equity of 1.95% and a negative net margin of 2.19%. Penumbra’s quarterly revenue was up 24.9% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.04) EPS. equities research analysts expect that Penumbra will post -0.15 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This report was first reported by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another site, it was stolen and reposted in violation of international copyright & trademark law. The original version of this report can be read at https://www.americanbankingnews.com/2017/12/15/penumbra-inc-pen-receives-consensus-recommendation-of-strong-buy-from-analysts.html.

Penumbra Company Profile

Penumbra, Inc is a healthcare company focused on interventional therapies. The Company designs, develops, manufactures and markets medical devices. It has a portfolio of products that addresses medical conditions and clinical needs across two markets, neuro and peripheral vascular. The conditions that its products address include ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures.

Get a free copy of the Zacks research report on Penumbra (PEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.